Switzerland (CH)

ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL (2022) D'Agostino MA, Boers M, Schett G, Conaghan PG, Naredo E, Mandl P, Carron P, et al. Conference contribution RESPONSIVENESS OF A COMBINED POWER DOPPLER AND GREYSCALE ULTRASOUND SCORE FOR ASSESSING SYNOVITIS AT JOINT LEVEL IN PSORIATIC ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO CSDMARDS: DATA FROM THE ULTIMATE TRIAL (2022) D'Agostino MA, Boers M, Gaillez C, Gamez C, Ventura L, Padovano JRI, Mandl P, et al. Conference contribution "EFFECTIVE LUNG AGE" IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL (2022) Maher T, Bourdin A, Volkmann E, Vettori S, Distler J, Alves M, Stock C, Distler O Conference contribution DEVELOPING A SCREENING TOOL FOR THE DETECTION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS:THE ILD-RISC RISK SCORE (2022) Bruni C, Tofani L, Fretheim H, Liem S, Velauthapillai A, Bjorkekjaer J, Barua I, et al. Conference contribution Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial. (2022) Hecht M, Eckstein M, Kallies A, Klautke G, Illmer T, von der Grün J, Laban S, et al. Conference contribution THE FMF&AID SURVEY - A PATIENT ORGANIZATION DRIVEN SURVEY FOR AUTOINFLAMMATORY DISEASES (2022) Rech J, Tascilar K, Tufan A, Gattorno M, Kuemmerle-Deschner JB, Ozen S, Krickau T, et al. Conference contribution SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL (2022) Venhoff N, Schmidt WA, Bergner R, Rech J, Unger L, Tony HP, Mendelson M, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IGD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Oommen P, Kallinich T, Rech J, Blank N, Weber-Arden J, Kuemmerle-Deschner JB Conference contribution DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS (2022) Kondo M, Suzuki T, Kawano Y, Kojima S, Miyashiro M, Matsumoto A, Kania G, et al. Journal article